In 2021, the Center for Drug Evaluation of the National Medical Products Administration (NMPA) in China approved 1,559 Investigational New Drug (IND) applications for innovative drugs. Almost all approvals were granted to chemical drugs or biopharmaceuticals, with less than 30 granted to innovative Traditional Chinese Medicine (TCM).
Investigational New Drug (IND)
An Investigational New Drug (IND) is a drug or biopharmaceutical product that is not yet approved for general use by the regulatory body while being used in clinical trials to examine its efficacy and safety. An IND application is the first step in the drug evaluation process, and the prerequisite for a drug product to enter its clinical trial phase.
Innovative drug industry in China
The first Chinese innovative drug, Icotinib (trade name Conmana), treating non-small-cell lung cancer, was launched in 2011. Since 2015, the Chinese government has introduced annual policies to promote innovations in the pharmaceutical industry. The development of domestically made innovative drugs has reduced the financial burden on patients and driven down the prices of imported medicine. Over 100 innovative drugs are now covered by medical insurance in China, with a considerable number being targeted drugs and biological products for the treatment of cancer.
Number of Investigational New Drug (IND) applications for innovative drugs granted approval in China from 2018 to 2021, by drug type
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
National Medical Products Administration. (June 1, 2022). Number of Investigational New Drug (IND) applications for innovative drugs granted approval in China from 2018 to 2021, by drug type [Graph]. In Statista. Retrieved November 21, 2024, from https://www.statista.com/statistics/1319956/china-number-of-investigational-new-drug-applications-of-innovative-drugs-approved/
National Medical Products Administration. "Number of Investigational New Drug (IND) applications for innovative drugs granted approval in China from 2018 to 2021, by drug type." Chart. June 1, 2022. Statista. Accessed November 21, 2024. https://www.statista.com/statistics/1319956/china-number-of-investigational-new-drug-applications-of-innovative-drugs-approved/
National Medical Products Administration. (2022). Number of Investigational New Drug (IND) applications for innovative drugs granted approval in China from 2018 to 2021, by drug type. Statista. Statista Inc.. Accessed: November 21, 2024. https://www.statista.com/statistics/1319956/china-number-of-investigational-new-drug-applications-of-innovative-drugs-approved/
National Medical Products Administration. "Number of Investigational New Drug (Ind) Applications for Innovative Drugs Granted Approval in China from 2018 to 2021, by Drug Type." Statista, Statista Inc., 1 Jun 2022, https://www.statista.com/statistics/1319956/china-number-of-investigational-new-drug-applications-of-innovative-drugs-approved/
National Medical Products Administration, Number of Investigational New Drug (IND) applications for innovative drugs granted approval in China from 2018 to 2021, by drug type Statista, https://www.statista.com/statistics/1319956/china-number-of-investigational-new-drug-applications-of-innovative-drugs-approved/ (last visited November 21, 2024)
Number of Investigational New Drug (IND) applications for innovative drugs granted approval in China from 2018 to 2021, by drug type [Graph], National Medical Products Administration, June 1, 2022. [Online]. Available: https://www.statista.com/statistics/1319956/china-number-of-investigational-new-drug-applications-of-innovative-drugs-approved/
